Vaccine for diabetes possible this decade, creating a potential $2.4 billion market by 2020, says Report

In the not-too-distant future we could see diabetes, the seventh leading cause of death in the USA, treated with a vaccine. Several vaccine candidates are in the pipeline, creating a possible $2.4 billion market for diabetes vaccine products by 2020, according to health care market research publisher Kalorama Information, which recently published a survey of emerging vaccine products titled: What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline.

Type 1 diabetes currently afflicts 35,000 people in the USA and about 700,000 people worldwide each year. Type 2 diabetes affects more than 16 million Americans and over 200 million people worldwide.

Currently, other than a humanized anti-CD3 antibody with considerable side effects, there is no other means to reverse new-onset type 1 diabetes. People with type 2 disease must control their blood sugar levels with diet and exercise, and approximately 78% also take prescription medications to help control their condition. However, they remain at risk for a large number of associated conditions including foot ulcers, heart disease, kidney failure, and various skin conditions.